Samaritan Awards Contract for HIV Monotherapy Trial to LabConnect

Samaritan Pharmaceuticals has selected LabConnect to provide central lab testing services for its upcoming monotherapy trial for HIV patients.

The trial, titled "A multicenter, double-blind, randomized, placebo-controlled, study of orally administered SP01A as monotherapy for the treatment of HIV-infected patients," is designed to assess the efficacy and safety of orally administered SP01A, as monotherapy for HIV-infected patients with evidence of resistance to currently available antiretroviral therapy.